The design objective of this study was to evaluate the effect of Helicobacter pylori eradication in reducing gastrointestinal bleeding in patients under treatment with aspirin and clopidogrel. Inclusion criteria included patients receiving the theraputic regimen of aspirin and clopidogrel in acute coronary syndrome and positive Helicobacter pylori stool antigen test. Exclusion criteria included a history of gastrointestinal bleeding, history of Helicobacter pylori eradication, pregnancy, cirrhosis, Patients with any medical history of any malignancy, history of peptic disease proven by endoscopy, acute or chronic renal failure, decompensated heart failure, and other serious health conditions. After the initial assessment, one hundred and forty patients were randomly divided into treatment and control groups. The two groups are matched in terms of factors such as age, sex, underlying disease (diabetes, hypertension), type of acute coronary syndrome, history of aggressive medical intervention (coronary stenting with balloon angioplasty), smoking and corticosteroid consumption. Patients in the control group received only pantoprazole and placebo while treatment group, received Standard Triple-Drug Therapy for Helicobacter pylori Eradication including amoxicillin, clarithromycin and pantoprazole over ten days. After 4 weeks of eradication therapy by stool antigen test, patients in the treatment group are examined. Once eradication is confirmed, Patients will be assessed quarterly for gastrointestinal bleeding. Deaths due to cardiovascular events or gastrointestinal complications are recorded. After three months, patients of both groups are compared. The primary objective was to reduce gross gastrointestinal bleeding and decreasing gastrointestinal symptoms such as dyspepsia, heart failure or recurrent thrombotic events during the study period were selected as secondary targets.